Cancer drug resistance presents a major barrier to continued successful treatment of
malignancies. Current therapies inhibiting proteins indicated in cancer progression are …

Simple Summary Breast and prostate cancers are serious public health issues that create
considerable burden to both people and healthcare systems worldwide. Cancer is a …

Background CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA
(RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study …

Yes-associated protein (YAP) is an effector of the Hippo tumor suppressor pathway. The
functional significance of YAP in prostate cancer has remained elusive. In this study, we first …

Prostate cancer is the most common type of cancer among men and the second most
frequent cause of cancer-related mortality around the world. The progression of advanced …

The role of the androgen receptor (AR) signaling axis in the progression of prostate cancer
is a cornerstone to our understanding of the molecular mechanisms causing castration …

Nucleotide‐based drugs, such as antisense oligonucleotides (ASOs), have unique
advantages in treating human diseases as they provide virtually unlimited ability to target …

Prostate cancer is the second most common cancer in men worldwide1. Outcomes for
patients with early-stage prostate cancer (stage I/II) are good, with over 90% progression …

Metastasis is one of the most important factors related to prostate cancer therapeutic
efficacy. In previous studies, shikonin, an active naphthoquinone isolated from the Chinese …

Background: With prostate cancer being the fifth-greatest cause of cancer mortality in 2020,
there is a dire need to expand the available treatment options. Castration-resistant prostate …